The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.
Akira Inoue
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - AstraZeneca; Boehringer Ingelheim; Pfizer
Yukio Hosomi
No relevant relationships to disclose
Makoto Maemondo
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Terufumi Kato
No relevant relationships to disclose
Kazuhisa Takahashi
No relevant relationships to disclose
Yuka Fujita
No relevant relationships to disclose
Akihiko Gemma
No relevant relationships to disclose
Toshiyuki Harada
No relevant relationships to disclose
Satoshi Oizumi
No relevant relationships to disclose
Koichi Minato
No relevant relationships to disclose
Satoshi Morita
Honoraria - Lilly
Toshihiro Nukiwa
Consultant or Advisory Role - Boehringer Ingelheim; Shionogi
Honoraria - Kyowa Hakko Kirin; Novartis; Shionogi